The Good,the Bad,and the Ugly: Sodium–Glucose Cotransporter-2 Inhibitors (Gliflozins) and Perioperative Diabetes

Peters A.L. , Buschur E.O. , Buse J.B. , Cohan P. , Diner J.C. , Hirsch I.B. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1687–1693.

Rosenstock J. , Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 9: 1638–1642.

Isaacs M. , Tonks K.T. , Greenfield J.R. Euglycaemic diabetic ketoacidosis in patients using sodium glucose co-transporter 2 inhibitors. Intern Med J 2017; 6: 701–704.

Chacko B. , Whitley M. , Beckmann U. , Murray K. , Rowley M. Postoperative euglycaemic diabetic ketoacidosis associated with sodium–glucose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the literature. Anaesth Intensive Care 2018; 46: 215–219.

Hoffman C. , Green M. , Megafu O. Sodium-glucose linked transporter 2 inhibitor-associated perioperative euglycaemic diabetic ketoacidosis: a case for a perioperative guideline. Anaesth Intensive Care 2017; 6: 758.

Lau A. , Bruce S. , Wang E. , Ree R. , Rondi K. , Chau A. Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycaemic ketoacidosis in three patients after cardiac surgery. Can J Anesth 2018; 1: 1–6.

Bonanni F. , Fei P. , Fitzpatrick L. Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin. Surg Obes Relat Dis 2016; 1: e11–12.

Sleiwah A. , McBride M. , Black C.E. Euglycaemic ketoacidosis: a potential new hazard to plastic surgery day case and inpatient procedures. BMJ Case Rep 2017; 220253.

Wood T. , Pang A.J. , Hallet J. , Greig P. Euglycaemic ketoacidosis in a postoperative whipple patient using canagliflozin. BMJ Case Rep 2016; bcr2016216607.

Heerspink H.J. , Perkins B.A. , Fitchett D.H. , Husain M. , Cherney D.Z. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation 2016; 10: 752–772.

Zinman B. , Wanner C. , Lachin J.M. , Fitchett D. , Bluhmki E. , Hantel S. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 22: 2117–2128.

Neal B. , Perkovic V. , Mahaffey K.W. , De Zeeuw D. , Fulcher G. , Erondu N. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 7: 644–657.

Wanner C. , Inzucchi S.E. , Lachin J.M. , Fitchett D. , von Eynatten M. , Mattheus M. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 4: 323–334.

Data from PBS Expenditure and Prescriptions (http://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions). Accessed 16/1/2018.

https://www.fda.gov/Drugs/DrugSafety/ucm475463.htm) 5-18-2016 FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections 12-4-2015. Accessed 16/1/2018.

Tang H. , Li D. , Wang T. , Zhai S. , Song Y. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2016; 39: 123–124.

Monami M. , Nreu B. , Zannoni S. , Lualdi C. , Mannucci E. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. Diabetes Res Clin Pract 2017; 130: 53–60.

Fadini G.P. , Bonora B.M. , Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 2017; 60: 1385–1389.

Goldenberg R.M. , Berard L.D. , Cheng A.Y. , Gilbert J.D. , Verma S. , Woo V.C. , Yale J.F. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther 2016; 38: 2654–2664.

Burke K.R. , Schumacher C.A. , Harpe S.E. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy 2017; 37: 187–194.

Peacock S.C. , Lovshin J.A. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting. Can J Anesth 2018; 2: 143–147.

Handelsman Y. , Henry R.R. , Bloomgarden Z.T. , Dagogo-Jack S. , DeFronzo R.A. , Einhorn D. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 2016; 22: 753–762.

Munro J.F. , Campbell I.W. , McCuish A.C. , Duncan L.J. Euglycaemic diabetic ketoacidosis. Br Med J 1973; 2: 578–580.

Peacock S.C. , Lovshin J.A. , Cherney D.Z. Perioperative considerations for the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Anesth Analg 2018; 699–704.

DeCou J.A. , Sams S.H. New diabetes medications raise new perioperative concerns for the anesthesiologist. Anesth Analg 2018; 126: 390–392.

European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes EMA/265224/2016 2016 Feb 11 available at URL: -http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/02/news_detail_002468.jsp&mid=WC0b01ac058004d5c1. Accessed 29/1/2018.

Carlson C.J. , Santamarina M.L. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Saf 2016; 10: 1401–1412.

Hirsch I.B. , Emmett M. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment. Nathan D.M. , Mulder J.E. , eds. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com.acs.hcn.com.au. Accessed on 26/1/2018.